Call Us: 1.800.873.5297


Recall Issued by Hi-Tech Pharmaceuticals For Undeclared Ingredients in Stamina-Rx

Yesterday on June 15, 2009 Hi-Tech Pharmaceuticals recalled its weight loss supplement Stamina-Rx. Stamina-Rx contains benzamidenafil, an undeclared and not FDA-approved ingredient.


Hi-Tech Pharmaceuticals, Inc. of Norcross, GA manufacturers Stamina-Rx.


On May 1, 2009, the FDA notified Hi-Tech that its lab analysis of Lot 08141578, Exp. 9/10 of Stamina-Rx contains − benzamidenafil − a Phosphodiesterase Type 5 (PDE5) inhibitor. PDE5 inhibitors, like FDA-approved sildenafil, tadalafil, and vardenafil treat erectile dysfunction (ED).


Benzamidenafil is not FDA-approved, and poses a threat to consumers. Benzamidenafil can interact with nitrates found in some prescription drugs (such as nitroglycerin) and can lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates and may be most susceptible to adverse effects from this product.


In addition to the one lot described above, Hi-Tech is recalling all other lots of Stamina-Rx because it is an unapproved new drug and misbranded new drug in violation of the Federal Food, Drug and Cosmetic Act (the Act). Stamina-Rx is not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in its labeling posted on certain web-based and print media.


Hi-Tech has been under a Consent Decree of Permanent Injunction with the FDA since September 23, 2003. In accordance with the Decree, the FDA determined that additional corrective actions were necessary for Hi-Tech to achieve compliance with the Act and the Decree and therefore, on May 1, 2009 the FDA ordered Hi-Tech to recall all lots of Stamina-Rx to the consumer level.


Customers who have this product in their possession should stop using it immediately. For more information regarding the recall contact: Hi-Tech Pharmaceuticals, Inc., Norcross, GA 30071 at toll-free 1-888-855-7919 from 9:00 AM – 5:00 PM EST.


Please report any adverse events associated with Stamina-Rx to the FDA’s MedWatch program.


The FDA can be contacted via:
Online at
Phone at 1-800-FDA-1088
Fax at 1-800-FDA-0178, using the MedWatch Form 3500
(available at getforms.htm)
Mail, using the postage-paid MedWatch Form 3500 (see above), to MedWatch, 5600
Fishers Lane,Rockville,MD20852-9787




For more information please see:

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.